Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

NCT03345810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Metastatic Lung Cancer
Non Small Cell Lung Cancer
Lung Adenocarcinoma Metastatic
Large Cell Lung Carcinoma Metastatic

Interventions

DRUG: Durvalumab
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: nab-Paclitaxel
DRUG: Carboplatin

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]